Autolus Therapeutics plc (NASDAQ:AUTL) Shares Sold by Perpetual Ltd

Perpetual Ltd reduced its stake in Autolus Therapeutics plc (NASDAQ:AUTL) by 33.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,599,252 shares of the company’s stock after selling 801,160 shares during the period. Perpetual Ltd’s holdings in Autolus Therapeutics were worth $5,805,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of AUTL. Sierra Summit Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the 4th quarter valued at $275,000. Perceptive Advisors LLC acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth about $11,793,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Autolus Therapeutics by 66.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 27,034 shares of the company’s stock valued at $172,000 after purchasing an additional 10,771 shares during the period. Privium Fund Management B.V. grew its holdings in shares of Autolus Therapeutics by 43.2% in the first quarter. Privium Fund Management B.V. now owns 50,058 shares of the company’s stock valued at $319,000 after purchasing an additional 15,091 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Autolus Therapeutics by 2,603.8% during the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock worth $736,000 after buying an additional 111,131 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Up 3.3 %

AUTL stock opened at $4.11 on Friday. The company’s 50 day moving average price is $3.89 and its 200 day moving average price is $4.20. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -3.43 and a beta of 2.04. Autolus Therapeutics plc has a fifty-two week low of $2.21 and a fifty-two week high of $7.45. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). On average, equities research analysts anticipate that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday, June 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Autolus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $8.70.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.